Cost effectiveness after a pancreaticoduodenectomy: bolstering the volume argument

HPB (Oxford). 2014 Dec;16(12):1056-61. doi: 10.1111/hpb.12309. Epub 2014 Jul 16.

Abstract

Background: The cost implication of variability in pancreatic surgery is not well described. It was hypothesized that for a pancreaticoduodenectomy (PD), lower volume centres demonstrate worse peri-operative outcomes at higher costs.

Methods: From 2009-2011, 9883 patients undergoing a PD were identified from the University HealthSystems Consortium (UHC) database and stratified into quintiles by annual hospital case volume. A decision analytic model was constructed to assess cost effectiveness. Total direct cost data were based on Medicare cost/charge ratios and included readmission costs when applicable.

Results: The lowest volume centres demonstrated a higher peri-operative mortality rate (3.5% versus 1.3%, P < 0.001) compared with the highest volume centres. When both index and readmission costs were considered, the per-patient total direct cost at the lowest volume centres was $23,005, or 10.9% (i.e. $2263 per case) more than at the highest volume centres. One-way sensitivity analyses adjusting for peri-operative mortality (1.3% at all centres) did not materially change the cost effectiveness analysis. Differences in cost were largely recognized in the index admission; readmission costs were similar across quintiles.

Conclusions: For PD, low volume centres have higher peri-operative mortality rates and 10.9% higher cost per patient. Performance of PD at higher volume centres can lead to both better outcomes and substantial cost savings.

Publication types

  • Comparative Study

MeSH terms

  • Cost Savings
  • Cost-Benefit Analysis
  • Databases, Factual
  • Decision Support Techniques
  • Hospital Charges
  • Hospital Costs*
  • Hospitals, High-Volume*
  • Hospitals, Low-Volume / economics*
  • Humans
  • Length of Stay / economics
  • Medicare / economics
  • Models, Economic
  • Pancreatic Neoplasms / economics*
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / surgery*
  • Pancreaticoduodenectomy / adverse effects
  • Pancreaticoduodenectomy / economics*
  • Pancreaticoduodenectomy / mortality
  • Patient Readmission / economics
  • Postoperative Complications / economics
  • Time Factors
  • Treatment Outcome
  • United States